VALIDATION OF A PATIENT REPORTED OUTCOME MEASURE (PROM) OF OVARIAN CANCER SYMPTOMS AND TREATMENT RELATED CONCERNS (MOST-OSI) WITH CHEMOTHERAPY IN RECURRENT OVARIAN CANCER (ROC).

被引：0
|
作者：
King, M. [1 ]
Stockler, M. [2 ]
O'Connell, R. [2 ]
Joly, F. [3 ]
Lanceley, A. [4 ]
Hilpert, F. [5 ]
Okamoto, A. [6 ]
Aotani, E. [7 ]
Pignata, S. [8 ]
Donnellan, P. [9 ]
Oza, A. [10 ]
Avall-Lundqvist, E. [11 ]
Berek, J. [12 ]
Buizen, L. [2 ]
Sjoquist, K. [2 ]
Butow, P. [1 ]
Friedlander, M. [13 ]
Gillies, K. [2 ]
Martyn, J. [2 ]
机构：
[1] Univ Sydney, Psychooncol Res Grp, Sydney, NSW 2006, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[3] Ctr Francoise Baclesse, GINECO, Caen, France
[4] UCL, London, England
[5] Klin Gynakol & Gerburtshilfe, UKSH, Kiel, Germany
[6] Jikei Univ, Sch Med, Tokyo, Japan
[7] Kitisato Acad Res Org, Tokyo, Japan
[8] Natl Canc Inst, Naples, Jamaica
[9] Galway Univ Hosp, Galway, Ireland
[10] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[11] Linkoping Univ, NSGO, Linkoping, Sweden
[12] Stanford Womens Canc Ctr, Stanford, CA USA
[13] Prince Wales Hosp, ANZGOG, GCIG Symptom Benefit StudyGrp GCIG, Kingston, ON, Canada
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-1157
引用
收藏
页码：457 / 458
页数：2
相关论文
共 41 条
  • [31] Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice
    Campbell, Rachel
    King, Madeleine T.
    Stockler, Martin R.
    Lee, Yeh Chen
    Roncolato, Felicia T.
    Friedlander, Michael L.
    PATIENT-RELATED OUTCOME MEASURES, 2023, 14 : 111 - 126
  • [32] Introduction and validation of the open symptom framework: a public domain modular framework for patient-reported measurement of symptoms related to cancer and its treatment
    Sidey-Gibbons, Chris Chris
    Brown, G.
    Lu, S. C.
    Elrick, A.
    Tang, Y.
    Kaufman, M.
    Williams, M.
    Xu, C.
    Harrison, C.
    Swisher, C.
    QUALITY OF LIFE RESEARCH, 2024, 33 (09) : 2349 - 2358
  • [33] SystematiC nurse-led cONsultations based oN Electronic patient-reported outcome among women with ovarian- or endometrial Cancer during chemoTherapy - protocol for the CONNECT study
    Christiansen, Mille Guldager
    Jarden, Mary
    Bager, Louise
    Mirza, Mansoor Raza
    Pappot, Helle
    Piil, Karin
    ACTA ONCOLOGICA, 2022, 61 (05) : 602 - 607
  • [34] BASELINE PREDICTORS OF EARLY TREATMENT FAILURE IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) RECEIVING ≥3 LINES OF CHEMOTHERAPY- THE GYNAECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)
    Roncolato, Felicia
    O'Connell, Rachel
    Joly, Florence
    Lanceley, Anne
    Hilpert, Felix
    Okamoto, Aikou
    Aotani, Eriko
    Pignata, Sandro
    Donnellan, Paul
    Oza, Amit
    Avall-Lundqvist, Elizabeth
    Berek, Jonathan
    Sjoquist, Katrin
    Gillies, Kim
    Butow, PhyllisPhyllis
    Stockler, Martin
    King, Madeleine
    Friedlander, Michael
    Kok, Peey-Sei
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 125 - 125
  • [35] Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥3) recurrent ovarian cancer (ROC) receiving ≥3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).
    Roncolato, Felicia T.
    O'Connell, Rachel
    Joly, Florence
    Lanceley, Anne
    Hilpert, Felix
    Okamoto, Aikou
    Aotani, Eriko
    Pignata, Sandro
    Donnellan, Paul P.
    Oza, Amit M.
    Avall-Lundqvist, Elisabeth
    Berek, Jonathan S.
    Sjoquist, Katrin Marie
    Gillies, Kim
    Butow, Phyllis
    Stockler, Martin R.
    King, Madeleine Trudy
    Friedlander, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRa-positive, platinum-resistant ovarian cancer
    Konecny, Gottfried
    Moore, Kathleen
    Lebreton, Coriolan
    Weroha, Saravut
    Romeo Marin, Margarita
    McAvan, Lucy
    Colombo, Nicoletta
    O'Malley, David
    Coffman, Lan
    Roszak, Andrzej
    Shapira-Frommer, Ronnie
    Lalisang, Roy
    Cibula, David
    Barquin, Arantzazu
    Glasspool, Rosalind
    Stec, James
    Li, Lingling
    Method, Michael
    Hardy-Bessard, Anne Claire
    Van Gorp, Toon
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S11 - S12
  • [37] Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) - an Exploratory Analysis
    Vergote, I.
    Bidzinski, M.
    Kelley, J.
    Vasanthan, S.
    Runnebaum, I.
    Vermorken, J.
    Arranz, J. A.
    Almorin, E.
    Park, Y.
    Lisyanskaya, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S536 - S536
  • [38] PATIENT-REPORTED OUTCOME (PRO) RESULTS FROM THE AGO-OVAR 2.20/ENGOT-OV14/PENELOPE DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED PHASE III TRIAL EVALUATING CHEMOTHERAPY ± PERTUZUMAB FOR PLATINUM-RESISTANT OVARIAN CANCER (PROC)
    Hilpert, F.
    Greimel, E.
    Ottevanger, P.
    Rau, J.
    Lorusso, D.
    Kroep, J.
    Mirza, M. Raza
    Zeimet, A.
    Mitchell, L.
    Kurzeder, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 465 - 466
  • [39] Patient-reported outcome (PRO) results from the AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum-resistant ovarian cancer (PROC)
    Hilbert, F.
    Gropp-Meier, M.
    Schmalfeldt, B.
    Rau, J.
    Meier, W.
    Hasenburg, A.
    Belau, A.
    Vergote, I.
    Zorr, A.
    Hils, R.
    Gerber, B.
    du Bois, A.
    Marme, F.
    Mahner, S.
    Canzler, U.
    Lueck, H. -J.
    Grischke, E. -M
    Kurzeder, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 138 - 138
  • [40] Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study-Analysis of patient reported outcomes (PRO) on chemotherapy randomization.
    Basen-Engquist, Karen
    Huang, Helen Q.
    Herzog, Thomas J.
    Armstrong, Deborah Kay
    Sabbatini, Paul
    Walker, Joan L.
    Kim, Byoung Gie
    Fujiwara, Keiichi
    Tewari, Krishnansu Sujata
    O'Malley, David M.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345